Session Details

Title
Hemophilia Treatment Centers
Date
Feb 01, 2022
Time
3:45PM - 5:00PM
Room/Location
Marriott Ballroom 10-11
Track
Stakeholder Breakout Sessions
Group(s)
3
Description
This session will focus exclusively on matters impacting Hemophilia Treatment Centers (HTCs), with an emphasis on 340B issues. Likely topics include HRSA's oversight efforts, including audits, Medicaid billing and reimbursement issues, and protecting program income. This session will also be an opportunity to discuss other issues impacting your HTC, such as HTCs as the Gold Standard of Care.

Learning Objectives:
  • Identify 340B issues that are unique to HTCs
  • List key developments in the 340B program
  • Describe current challenges facing the program
  • Discuss issues beyond 340B affecting HTCs' finances, compliance, and operations

Session Speaker(s)

NameTitleCompany
Jeff BlakePresident and Chief Executive OfficerHemophilia Alliance340BWC2233786Blake
Michael GlombPartnerFeldesman Leifer LLP340BWC223433Glomb
Elizabeth KaranPrincipal Attorney/PrincipalKaran Legal Group/Artemis Policy Group340BWC2228011Karan
Joe PuglieseAdvisor to the CEOHemophilia Alliance340BWC223697Pugliese
Sean SinghSenior Vice President, Marketing and OperationsHemophilia Alliance340BWC223784Singh